Impact of cumulative incarceration and the post-release period on syringe-sharing among people who inject drugs in Tijuana, Mexico: a longitudinal analysis.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
10 2021
Historique:
revised: 14 12 2020
received: 15 09 2020
accepted: 02 02 2021
pubmed: 24 2 2021
medline: 30 9 2021
entrez: 23 2 2021
Statut: ppublish

Résumé

Syringe-sharing among people who inject drugs, which can occur during incarceration and post-release, has been linked with increased risk of blood-borne infections. We aimed to investigate the cumulative effect of repeated incarceration and the post-release period on receptive syringe-sharing. Ongoing community-based cohort, recruited through targeted sampling between 2011 and 2012 with 6-month follow-ups. Tijuana, Mexico. Sample of 185 participants (median age 35 years; 67% female) with no history of incarceration at study entry, followed to 2017. Cumulative incarceration and post-release period were constructed from incarceration events reported in the past 6 months for each study visit. Receptive syringe-sharing in the past 6 months was assessed as a binary variable. We used logistic regression with generalized estimating equations to examine the association between cumulative incarceration events and the post-release period with receptive syringe-sharing over time. Missing data were handled through multiple imputation. At baseline, 65% of participants engaged in receptive syringe-sharing in the prior 6 months. At follow-up, 150 (81%) participants experienced a total of 358 incarceration events [median = 2, interquartile range (IQR) = 1-3]. The risk of receptive syringe-sharing increased with the number of repeated incarcerations. Compared with never incarcerated, those with one incarceration had 1.28 [95% confidence interval (CI) = 0.97-1.68] higher adjusted odds of syringe-sharing; two to three incarcerations, 1.42 (95% CI = 1.02-1.99) and more than three incarcerations, 2.10 (95% CI = 1.15-3.85). Participants released within the past 6 months had 1.53 (95% CI = 1.14-2.05) higher odds of sharing syringes compared with those never incarcerated. This post-release risk continued up to 1.5 years post-incarceration (adjusted odds ratio = 1.41, 95% CI = 1.04-1.91), but then waned. A longitudinal community cohort study among people who inject drugs suggested that the effects of incarceration on increased injecting risk, measured through syringe-sharing, are cumulative and persist during the post-release period.

Sections du résumé

BACKGROUND AND AIMS
Syringe-sharing among people who inject drugs, which can occur during incarceration and post-release, has been linked with increased risk of blood-borne infections. We aimed to investigate the cumulative effect of repeated incarceration and the post-release period on receptive syringe-sharing.
DESIGN
Ongoing community-based cohort, recruited through targeted sampling between 2011 and 2012 with 6-month follow-ups.
SETTING
Tijuana, Mexico.
PARTICIPANTS
Sample of 185 participants (median age 35 years; 67% female) with no history of incarceration at study entry, followed to 2017.
MEASUREMENTS
Cumulative incarceration and post-release period were constructed from incarceration events reported in the past 6 months for each study visit. Receptive syringe-sharing in the past 6 months was assessed as a binary variable. We used logistic regression with generalized estimating equations to examine the association between cumulative incarceration events and the post-release period with receptive syringe-sharing over time. Missing data were handled through multiple imputation.
FINDINGS
At baseline, 65% of participants engaged in receptive syringe-sharing in the prior 6 months. At follow-up, 150 (81%) participants experienced a total of 358 incarceration events [median = 2, interquartile range (IQR) = 1-3]. The risk of receptive syringe-sharing increased with the number of repeated incarcerations. Compared with never incarcerated, those with one incarceration had 1.28 [95% confidence interval (CI) = 0.97-1.68] higher adjusted odds of syringe-sharing; two to three incarcerations, 1.42 (95% CI = 1.02-1.99) and more than three incarcerations, 2.10 (95% CI = 1.15-3.85). Participants released within the past 6 months had 1.53 (95% CI = 1.14-2.05) higher odds of sharing syringes compared with those never incarcerated. This post-release risk continued up to 1.5 years post-incarceration (adjusted odds ratio = 1.41, 95% CI = 1.04-1.91), but then waned.
CONCLUSIONS
A longitudinal community cohort study among people who inject drugs suggested that the effects of incarceration on increased injecting risk, measured through syringe-sharing, are cumulative and persist during the post-release period.

Identifiants

pubmed: 33620749
doi: 10.1111/add.15445
pmc: PMC8380753
mid: NIHMS1673355
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2724-2733

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA039073
Pays : United States
Organisme : NIDA NIH HHS
ID : DP2 DA049295
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147490
Pays : United States
Organisme : NIDA NIH HHS
ID : R37 DA019829
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIDA NIH HHS
ID : K01 DA043421
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States

Informations de copyright

© 2021 Society for the Study of Addiction.

Références

Annu Rev Public Health. 2012 Apr;33:325-39
pubmed: 22224880
Int J Prison Health. 2015;11(3):183-92
pubmed: 26277925
Int J Drug Policy. 2017 Sep;47:230-238
pubmed: 28633998
Drug Alcohol Rev. 2018 Jan;37(1):128-136
pubmed: 28337798
Int J Drug Policy. 2018 Apr;54:1-8
pubmed: 29306177
Harm Reduct J. 2011 Apr 08;8:7
pubmed: 21477299
J Psychoactive Drugs. 2005 Sep;37(3):333-9
pubmed: 16295018
Epidemiol Rev. 2020 Jan 31;42(1):27-40
pubmed: 33184637
Harm Reduct J. 2014 Feb 12;11:4
pubmed: 24520885
Int J Drug Policy. 2015 Feb;26 Suppl 1:S27-32
pubmed: 25265900
Lancet. 2010 Aug 14;376(9740):493-5
pubmed: 20650521
Int J Drug Policy. 2018 Apr;54:18-25
pubmed: 29367011
Int J Drug Policy. 2020 Jan;75:102601
pubmed: 31775080
BMC Public Health. 2009 May 27;9:156
pubmed: 19473508
J Int AIDS Soc. 2011 May 19;14:26
pubmed: 21595957
Lancet HIV. 2018 Nov;5(11):e617-e628
pubmed: 30197101
AIDS Behav. 2015 Jun;19(6):987-95
pubmed: 25613593
Lancet HIV. 2017 Aug;4(8):e357-e374
pubmed: 28515014
Lancet. 2016 Sep 10;388(10049):1089-1102
pubmed: 27427453
Subst Use Misuse. 2017 Jan 28;52(2):214-222
pubmed: 27767367
Drug Alcohol Depend. 2009 Jul 1;103(1-2):52-8
pubmed: 19386448
Lancet Infect Dis. 2018 Dec;18(12):1397-1409
pubmed: 30385157
J Acquir Immune Defic Syndr. 2015 Jun 1;69 Suppl 2:S176-81
pubmed: 25978485
AIDS. 2014 Jan;28 Suppl 1:S35-46
pubmed: 24468945
Lancet Infect Dis. 2018 Dec;18(12):1301-1302
pubmed: 30385159
Drug Alcohol Depend. 2015 Feb 1;147:196-202
pubmed: 25496706
Addiction. 2008 Jan;103(1):101-8
pubmed: 18028520
Lancet Public Health. 2018 Sep;3(9):e429-e437
pubmed: 30122559
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Drug Alcohol Depend. 2018 Apr 1;185:298-304
pubmed: 29482055
Eur J Public Health. 2015 Dec;25(6):1089-94
pubmed: 26381650
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Lancet. 2016 Sep 10;388(10049):1115-1126
pubmed: 27427456
Addict Sci Clin Pract. 2012;7:3
pubmed: 22966409
Drug Alcohol Depend. 2012 Nov 1;126(1-2):156-60
pubmed: 22658284
Fam Med Community Health. 2020 Feb 16;8(1):e000262
pubmed: 32148735
Drug Alcohol Rev. 2008 Nov;27(6):693-9
pubmed: 19378451
Lancet. 2016 Apr 2;387(10026):1427-1480
pubmed: 27021149
Drug Alcohol Rev. 2019 Mar;38(3):254-263
pubmed: 30569550
Int J Drug Policy. 2008 Aug;19(4):332-8
pubmed: 17900888
J Clin Epidemiol. 2006 Oct;59(10):1087-91
pubmed: 16980149
Public Health Rep. 2005 Mar-Apr;120(2):150-6
pubmed: 15842116
Lancet. 2010 Jul 24;376(9737):268-84
pubmed: 20650523

Auteurs

Carlos D Rivera Saldana (CD)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
School of Public Health, San Diego State University, San Diego, CA, USA.

Leo Beletsky (L)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
School of Law and Bouve College of Health Sciences, Northeastern University, Boston, MA, USA.

Annick Borquez (A)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Susan M Kiene (SM)

School of Public Health, San Diego State University, San Diego, CA, USA.

Steffanie A Strathdee (SA)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

María Luisa Zúñiga (ML)

School of Social Work, San Diego State University, San Diego, CA, USA.

Natasha K Martin (NK)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Population Health Sciences, University of Bristol, Bristol, UK.

Javier Cepeda (J)

Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH